Jump to content

Melissa Palmer

Add links
From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by Medicalfrog (talk | contribs) at 23:33, 25 December 2020 (changed text; fixed ISBN). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Melissa Palmer, MD
Hepatologist and researcher in the field of liver disease
Born (1958-08-29) August 29, 1958 (age 66)
NationalityAmerican
EducationMedical Degree, Mount Sinai School of Medicine, 1985; Residency in Internal Medicine, Mount Sinai Beth Israel, 1985-88; Fellowship in Hepatology, Mount Sinai School of Medicine, 1988-89; Fellowship in Gastroenterology, Stony Brook University Hospital, 1989-91
Occupation(s)Chief Medical Officer, Gannex Pharma, a wholly owned company of Ascletis Pharma, Beijing, China
SpouseAlan Pressman (m. 1987)


Melissa Palmer, MD (born August 29, 1958) is an American Hepatologist. She is recognized for her research and treatment of hepatitis and liver disease. Palmer is the Chief Medical Officer of Gannex Pharma, a wholly owned company of Ascletis Pharma[1].

Early life and education

Palmer was born in New York City, New York. She grew up in Forest Hills, Queens and attended Forest Hills High School (New York). She attended Columbia University [2], graduating with a Bachelor of Science degree. Palmer attended medical school at the Mount Sinai School of Medicine, from which she graduated with a Doctor of Medicine degree in 1985.

Career

Palmer completed her internship and residency at Mount Sinai Beth Israel in Manhattan, New York, from 1985-1988, and completed a fellowship in Hepatology at Mount Sinai. Palmer also completed a Gastroenterology fellowship at Stony Brook University Hospital.

It was during her fellowship at Mount Sinai that Palmer became the first to publish research demonstrating that if an overweight person who has liver-related abnormalities (such a person is considered to have NAFLD) loses 10% of their body weight, it corrects these findings. Non-alcoholic Fatty Liver Disease (NAFLD) is the most common liver disease worldwide, occurring in in 30-40 percent of adults in the United States.[3] This research study[4], published in the medical journal Gastroenterology in 1990, has been cited in almost 500 medical research articles. In addition, Palmer, either as primary author or co-author, published several guidelines with colleagues from the Food and Drug Administration (FDA) the detection, assessment and management of drug induced liver injury (hepatotoxicity) among patients participating in clinical trials evaluating potential liver drugs.[5][6][7]

Palmer is the author of the book "Dr. Melissa Palmer's Guide to Hepatitis & Liver Disease" which is notable for being a comprehensive book on liver disease written for the general public and health care practitioners. Published in 2000, the book provides information on all facets of liver disease, including the function of the liver, liver blood tests, the symptoms and treatment of various liver diseases, cirrhosis, liver cancer, and the influence of lifestyle on liver disease. The book has been translated into several languages, including Spanish and Chinese. Palmer also co-authored and co-edited a medical textboook "The Gastrointestinal and Liver Disease Nutrition Desk Reference" with colleagues from Johns Hopkins Medical Center.

Palmer became the Chief Medical Officer of Gannex Pharma as of Dec. 2020. Prior to joining Gannex, she was Head of Liver Disease Clinical Development at Takeda Pharmaceutical Company. She has also held leadership positions at Shire Pharmaceuticals and Kadmon Corporation, where she was in charge of the global development of Non-alcoholic steatohepatitis (NASH) and other liver disease programs. Prior to joining the pharmaceutical industry, she was clinical professor at NYU Langone Medical Center. From 1991-2011, Palmer operated a solo medical practice focused on liver disease.

Selected Books

  • "Dr. Melissa Palmer's Guide to Hepatitis & Liver Disease"-- New Revised Edition May 2004. (PenguinRandomHouse--Avery Division) ISBN 9781583331880 ; Chinese version July 2008. (Jilin Press, Jilin China)
  • "Dr. Melissa Palmer's Guide to Hepatitis & Liver Disease"-- Original Edition January 1, 2000. (PenguinRandomHouse--Avery Division) ISBN 9781422350898 ; Taiwanese version 2001
  • "The Gastrointestinal and Liver Disease Nutrition Desk Reference", edited by Gerard Mullin,Laura Matarese and Melissa Palmer. Sept. 2011. (CRC Press) ISBN 9781439812648

Selected Book Chapters

  • "Integrative Weight Management: A Guide for Clinicians (Nutrition and Health)"-- Chapter on Non-Alcoholic Fatty Liver Disease. Gerald E. Mullin (Editor). May 2014. (Humana Press) ISBN 9781493905478
  • "Textbook of Natural Medicine" 4th Edition-- Chapter 173, on Hepatitis. Sept. 2012. (Elsevier) ISBN 9781437723335
  • "Encyclopedia of Plagues, Pestilence and Pandemics"-- Chapter on Hepatitis. Oct. 2008 (Greenwood Press) ISBN 9780313341014
  • "Encyclopedia of Science and Technology"-- Chapter on Cirrhosis. Feb. 2007. (McGraw-Hill) ISBN 9780071441438
  • "The Autoimmune Connection"-- Chapter on AutoImmune Hepatitis/PBC. April 2016. (McGraw-Hill) ISBN 9780071841221

Selected Academic Publications

  • Treem WR, Palmer M, Lonjon-Domanec I, Seekins D, Dimick-Santos L, Avigan MI, Marcinak JF, Dash A, Regev A, Maller E, Patwardhan M, Lewis JH, Rockey DC, Di Bisceglie AM, Freston JW, Andrade RJ, Chalasani N. Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis. Drug Saf. 2020 Nov 3. doi: 10.1007/s40264-020-01014-2. Epub ahead of print. PMID: 33141341.[8]
  • Newsome PN, Palmer M, Freilich B, Sheikh MY, Sheikh A, Sarles H, Herring R, Mantry P, Kayali Z, Hassanein T, Lee HM, Aithal GP; Volixibat in Adults study group. Volixibat in adults with non-alcoholic steatohepatitis: 24-week interim analysis from a randomized, phase II study. J Hepatol. 2020 Aug;73(2):231-240. doi: 10.1016/j.jhep.2020.03.024. Epub 2020 Mar 29. PMID: 32234329. [9]
  • Palmer M, Regev A, Lindor K, Avigan MI, Dimick-Santos L, Treem W, Marcinak JF, Lewis JH, Anania FA, Seekins D, Shneider BL, Chalasani N. Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease. Aliment Pharmacol Ther. 2020 Jan;51(1):90-109. doi: 10.1111/apt.15579. Epub 2019 Nov 25. PMID: 31762074; PMCID: PMC6972572.[10]
  • Regev A, Palmer M, Avigan MI, Dimick-Santos L, Treem WR, Marcinak JF, Seekins D, Krishna G, Anania FA, Freston JW, Lewis JH, Sanyal AJ, Chalasani N. Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis. Aliment Pharmacol Ther. 2019 Mar;49(6):702-713. doi: 10.1111/apt.15153. Epub 2019 Feb 13. PMID: 30761572; PMCID: PMC6593464.[11]
  • Tiessen RG, Kennedy CA, Keller BT, Levin N, Acevedo L, Gedulin B, van Vliet AA, Dorenbaum A, Palmer M. Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial. BMC Gastroenterol. 2018 Jan 5;18(1):3. doi: 10.1186/s12876-017-0736-0. PMID: 29304731; PMCID: PMC5756385.[12]
  • Palmer M, Jennings L, Silberg DG, Bliss C, Martin P. "A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis". BMC Pharmacol Toxicol. 2018 Mar 16;19(1):10. doi: 10.1186/s40360-018-0200-y. PMID: 29548345; PMCID: PMC5857122.[13]
  • Siebers N, Palmer M, Silberg DG, Jennings L, Bliss C, Martin PT. Absorption, Distribution, Metabolism, and Excretion of [14C]-Volixibat in Healthy Men: Phase 1 Open-Label Study. Eur J Drug Metab Pharmacokinet. 2018 Feb;43(1):91-101. doi: 10.1007/s13318-017-0429-7. PMID: 28702877; PMCID: PMC5794849.[14]
  • Palmer, Melissa. Letter to the Editor-- "Practice Guidelines on Non-Alcoholic Fatty Liver Disease". Hepatology. Feb. 2013 Vol.57(2):853[15]
  • Palmer, M., Rubin, R., Rustgi, V. and (2012), Randomised clinical trial: pre‐dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment‐naïve patients with chronic hepatitis C genotype 1. Aliment Pharmacol Ther, 36: 370-378.[16]
  • Manns, M; Palmer, M; Flisiak, R; DeJesus, E; Hazan, L, et al."A Phase-2b Trial to Evaluate the Safety, Tolerability and Efficacy of a Caspase Inhibitor, GS-9450, in Adults Failing PEG/RBV Therapy for Chronic HCV Infection". 46th Annual Meeting of the European Association for the Study of the Liver. March 30-Apr. 3 2011, Berlin Germany Oral Presentation #50[17]
  • Palmer M, Rubin R, Rustgi V; Taribavirin Viral Kinetic Study Group. "Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1". Aliment Pharmacol Ther. 2012 Aug;36(4):370-8. doi: 10.1111/j.1365-2036.2012.05188.x. Epub 2012 Jun 19. PMID: 22708649; PMCID: PMC3492905.[18]
  • Palmer M, Schaffner F. "Effect of weight reduction on hepatic abnormalities in overweight patients". Gastroenterology. 1990 Nov;99(5):1408-13. doi: 10.1016/0016-5085(90)91169-7. PMID: 2210247.[19]
  • Palmer M, Braly LF, Schaffner F. "The liver in acquired immune deficiency disease". Semin Liver Dis. 1987 Aug;7(3):192-202. doi: 10.1055/s-2008-1040576. PMID: 3317858.[20]
  • Lebovics E, Palmer M, Woo J, Schaffner F. "Outcome of primary sclerosing cholangitis. Analysis of long-term observation of 38 patients". Arch Intern Med. 1987 Apr;147(4):729-31. PMID: 3493746.[21]
  • Finkler NJ, Palmer M, Gonda M, Dreiling DA. "Nephelometric determination of immunoglobulins in exocrine pancreatic secretion: studies on patients with and without pancreatic disease". Mt Sinai J Med. 1979 May-Jun;46(3):339-40. PMID: 381903.[22]

Selected General Media Publications

  • "Weight Loss for a Healthy Liver". Prevention Magazine Vol.42, No.6, Pg.19. June 1990
  • "A Vaccine Against Hepatitis A". Newsday-- A letter to the Editor. April 9, 1998
  • "Are Herbs Beneficial?/ Is it Good Medicine?"-- interviewed and quoted. [23] TIME Magazine (cover story). Nov. 23, 1998
  • Hepatitis Vaccinations-- "So, is it Time to Give this a Shot?" [24] -- interviewed and quoted on hepatitis vaccinations PSI-S5. Los Angeles Times. Nov. 23, 1998
  • "Painkillers and the Liver". Cosmopolitan Magazine. May 2004
  • "Hepatitis C". Men's Fitness. Aug. 2006
  • "Colloidal Silver for Hepatitis". Money Magazine. June 2007
  • "Health Dangers of Parties Past". [25] Wall Street Journal. Sept. 20, 2010
  • "The Facts on Hepatitis; Where to Find Help". [26] Newsday. Jan. 3, 2011
  • "New Drugs OKd for Treating Hepatitis C" [27] Newsday. May, 25, 2011
  • "Collaboration on Hepatitis Drugs Lags". [28] New York Times. Apr. 20, 2012

Awards and Distinctions

  • Fellow of AASLD. 2014-present [29]
  • Medical Advisory Board, Greater New York Chapter of the American Liver Foundation. [30] 1991-present
  • Ediorial Board, Practical Gastroenterology. [31] 2009-present
  • Editorial Board, Journal of Gastrointestinal and Digestive System. 2012-present
  • Castle Connolly Best Doctors in New York Metro Area. 2004-2012
  • WEBMD Health and Liver Disease expert. 2010-2012
  • Member of WEBMD Medical Review Team. 2010-present

References

  1. ^ "Ascletis Pharma".
  2. ^ "Columbia University Alumni 1980-1984".
  3. ^ "NIH--Definition & Facts of NAFLD & NASH".
  4. ^ "Effect of weight reduction on hepatic abnormalities in overweight patients". PMID 2210247. {{cite journal}}: Cite journal requires |journal= (help)
  5. ^ "Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis". PMID 33141341. {{cite journal}}: Cite journal requires |journal= (help)
  6. ^ "Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease". PMID 31762074. {{cite journal}}: Cite journal requires |journal= (help)
  7. ^ "Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis". PMID 30761572. {{cite journal}}: Cite journal requires |journal= (help)
  8. ^ "Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis". PMID 33141341. {{cite journal}}: Cite journal requires |journal= (help)
  9. ^ "Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis". PMID 32234329. {{cite journal}}: Cite journal requires |journal= (help)
  10. ^ "Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis". PMID 31762074. {{cite journal}}: Cite journal requires |journal= (help)
  11. ^ "Consensus Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Adults with Chronic Viral Hepatitis and Adults with Cirrhosis Secondary to Hepatitis B, C and Nonalcoholic Steatohepatitis". PMID 30761572. {{cite journal}}: Cite journal requires |journal= (help)
  12. ^ "Safety, tolerability and pharmacodynamics of apical sodium-dependent bile acid transporter inhibition with volixibat in healthy adults and patients with type 2 diabetes mellitus: a randomised placebo-controlled trial". PMID 29304731. {{cite journal}}: Cite journal requires |journal= (help)
  13. ^ ""A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholic steatohepatitis"". PMID 29548345. {{cite journal}}: Cite journal requires |journal= (help)
  14. ^ "Absorption, Distribution, Metabolism, and Excretion of [14C]-Volixibat in Healthy Men: Phase 1 Open-Label Study". PMID 28702877. {{cite journal}}: Cite journal requires |journal= (help)
  15. ^ ""Practice Guidelines on Non-Alcoholic Fatty Liver Disease"". doi:10.1002/hep.25998. {{cite journal}}: Cite journal requires |journal= (help)
  16. ^ "Randomised clinical trial: pre‐dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment‐naïve patients with chronic hepatitis C genotype 1". doi:10.1111/j.1365-2036.2012.05188.x. {{cite journal}}: Cite journal requires |journal= (help)
  17. ^ ""A Phase-2b Trial to Evaluate the Safety, Tolerability and Efficacy of a Caspase Inhibitor, GS-9450, in Adults Failing PEG/RBV Therapy for Chronic HCV Infection"". doi:10.1016/S0168-8278(11)60128-1. {{cite journal}}: Cite journal requires |journal= (help)
  18. ^ "Randomised clinical trial: pre-dosing with taribavirin before starting pegylated interferon vs. standard combination regimen in treatment-naïve patients with chronic hepatitis C genotype 1"". PMID 22708649. {{cite journal}}: Cite journal requires |journal= (help)
  19. ^ ""Effect of weight reduction on hepatic abnormalities in overweight patients"". PMID 2210247. {{cite journal}}: Cite journal requires |journal= (help)
  20. ^ ""The liver in acquired immune deficiency disease"". PMID 3317858. {{cite journal}}: Cite journal requires |journal= (help)
  21. ^ ""Outcome of primary sclerosing cholangitis. Analysis of long-term observation of 38 patients"". PMID 3493746. {{cite journal}}: Cite journal requires |journal= (help)
  22. ^ ""Nephelometric determination of immunoglobulins in exocrine pancreatic secretion: studies on patients with and without pancreatic disease"". PMID 381903. {{cite journal}}: Cite journal requires |journal= (help)
  23. ^ "Are Herbs Beneficial?/ Is it Good Medicine?". Time Magazine.
  24. ^ ""So, is it Time to Give this a Shot?"". Los Angeles Times.
  25. ^ "Health Dangers of Parties Past". Wall Street Journal.
  26. ^ "The Facts on Hepatitis; Where to Find Help"". Newsday.
  27. ^ ""New Drugs OKd for Treating Hepatitis C"". Newsday.
  28. ^ ""Collaboration on Hepatitis Drugs Lags"". New York Times.
  29. ^ "AASLD Member Profile".
  30. ^ "American Liver Foundation, New York State Medical Advisory Council".
  31. ^ "Practical Gastroenterology Editorial Board".
Retrieved from "https://en.wikipedia.org/w/index.php?title=Melissa_Palmer&oldid=996331743"